RNS Number : 1993F Renalytix AI PLC 13 November 2020 Renalytix AI plc (" RenalytixAI " or the " Company ") RenalytixAI to Participate in the Stifel 2020 Healthcare Conference NEW YORK , November 13, 2020 - Renalytix AI plc (LSE : RENX) (NASDAQ: RNLX), an artificial intelligence-enabled
NEW YORK, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces the
RNS Number : 4449E Renalytix AI PLC 06 November 2020 Renalytix AI plc (" RenalytixAI " or the " Company ") Change of adviser NEW YORK , November 6, 2020 - Renalytix AI plc (LSE : RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on
NEW YORK, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, confirms that the
RNS Number : 9886D Renalytix AI PLC 02 November 2020 Renalytix AI plc (" RenalytixAI " or the " Company ") Posting of Annual Report & Accounts and Notice of AGM NEW YORK , November 2, 2020 - Renalytix AI plc (LSE : RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro
NEW YORK, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces its full
RNS Number : 3088D Renalytix AI PLC 27 October 2020 Renalytix AI plc (" RenalytixAI " or the " Company ") Full Year Report NEW YORK , October 27, 2020 - Renalytix AI plc (LSE : RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing
Renalytix AI plc ("RenalytixAI" or the "Company") Notice of results Analyst and Investor presentations NEW YORK , Oct. 16, 2020 /PRNewswire/ -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management
RNS Number : 2682C Renalytix AI PLC 16 October 2020 Renalytix AI plc (" RenalytixAI " or the " Company ") Notice of results Analyst and Investor presentations RenalytixAI To Announce Financial Results for Full Year Ended June 30, 2020 and Provide Corporate Update NEW YORK , October 16,
RNS Number : 9631B Renalytix AI PLC 13 October 2020 Not for release, publication or distribution, directly or indirectly, in whole or in part, in, into or within the United States , Australia , Canada , Hong Kong , Japan , New Zealand , the Republic of South Africa or any other jurisdiction where
